AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test measuring the neutralizing levels of anti-COVID-19 antibodies.
NeuCovix™ accurately categorizes blood serum
The company compared the NeuCovix™ with the pseudovirus-based gold standard test. Results indicated that the NeuCovix™ test precisely categorized serum form COVID-19 patients that had strongly neutralized the SARS-CoV-2 as well as serum from those that had neutralized the virus poorly. Interestingly there was no cross-reaction with serum for the NeuCovix™ test for patients with seasonal respiratory infections that include seasonal coronavirus, which is an indication that the test has almost 100% specificity for SARS-CoV-2.
The current tests that use live viruses are expensive, time-consuming, and need highly trained personnel working in a tightly managed lab environment in measuring neutralizing antibodies. On the other hand, the NeuCovix™ test is cheap, portable, and quick point-of-care tests that determine the neutralizing antibody level in less than ten minutes. Considering the NeuCovix™ tests are in line with virus assay, it could prove to be an effective and affordable tool in monitoring huge numbers of subjects receiving vaccines for antibody neutralizing.
NeuCovix™ test is faster and less expensive
Also, NeuCovix™ can be used in measuring neutralizing antibodies levels in patients under that are receiving convalescent plasma or hyperimmune globulin to enable healthcare providers to determine the ideal neutralizing antibodies dosing that is in line with favorable results. John Huemoeller II, the CEO of AXIM® Biotech, stated that they were delighted with the preliminary test results showed by NeuCovix™. He added that the difference the tests deliver in time of money and time for vaccine developers and blood centers is huge.
AXIM® Biotech’s wholly-owned subsidiary, Sapphire Biotech’s Chief Scientific Officer Sergei Svarovusky, said that there is still work that needs to be done EUA. Sergei said that the 10-minute test has shown almost similar protective immune outcomes in samples of plasma from patients with high and low titers compared to the other time consuming and expensive lab tests.
Mydecine Innovations Group Inc (OTCMKTS: MYCOF) Provides an Update on Spin-Out of Cannabis Assets in the United States
Post Views: 3 Mydecine Innovations Group Inc (OTCMKTS: MYCOF) recently announced that it has both mailed and filed its management information...
Tauriga Sciences, Inc. (OTCMKTS: TAUG) Sets up a Clinical Trial to Determine the effects of Cannabidiol on Pregnant Women with a Hyperemesis Gravidarum Diagnosis.
Post Views: 6 Nausea and vomiting are very common in early pregnancy, and the victims have to ingest multiple medications....
BetterLife Pharma Inc. (OTCMKTS: BETRF) Announce Initiation Of In Vitro Studies of AP-003 Against The Delta Variant of SARS-CoV-2
Post Views: 25 Depression impacts approximately 265 million people in the world. According to WHO, it is one of the...
Ayr Wellness Inc. (OTCMKTS: AYRWF) Signs a Binding Letter of Intent to Acquire PA Natural Medicine, LLC
Post Views: 25 Curiosity about cannabis is building by the day as more expert cultivators, manufactures, budtenders, and patient consultants...
Schwazze (OTCMKTS: SHWZ) Spends $6.7 Million to Acquire the Assets of Brow 2, LLC, Located in Denver, Colorado
Post Views: 39 Innovative thinking is what will keep the next era of the cannabis industry alive. This is according...
Valens Company Inc (OTCMKTS: VLNCF) Acquires Leading, Premium Craft Licensed producer, Citizen Stash Cannabis Corp
Post Views: 109 Valens Company Inc (OTCMKTS: VLNCF), a leading manufacturer of cannabis products, announced that it entered into an...